Clinical Trial Update: Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of 19#iSCLife®-CI, a human umbilical cord mesenchymal stem cell therapy for cerebral infarction patients in the convalescent period, has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Infarction

Drugs mentioned

• 19#iSCLife®-CI (human umbilical cord mesenchymal stem cell therapy)

Snippet

Sponsor: Sclnow Biotechnology Co., Ltd. | Conditions: Cerebral Infarction | Phase 1, Phase 2 | Status: SUSPENDED